1.80
price down icon1.64%   -0.03
after-market アフターアワーズ: 1.82 0.02 +1.11%
loading
前日終値:
$1.83
開ける:
$1.84
24時間の取引高:
1.00M
Relative Volume:
0.34
時価総額:
$179.60M
収益:
-
当期純損益:
$-37.34M
株価収益率:
-1.3235
EPS:
-1.36
ネットキャッシュフロー:
$-36.91M
1週間 パフォーマンス:
+1.69%
1か月 パフォーマンス:
-2.70%
6か月 パフォーマンス:
+78.22%
1年 パフォーマンス:
+55.17%
1日の値動き範囲:
Value
$1.78
$1.86
1週間の範囲:
Value
$1.75
$1.94
52週間の値動き範囲:
Value
$0.772
$2.2691

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name
名前
Sellas Life Sciences Group Inc
Name
セクター
Healthcare (1164)
Name
電話
(646) 200-5278
Name
住所
7 TIMES SQUARE, NEW YORK, NY
Name
職員
15
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
SLS's Discussions on Twitter

SLS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SLS
Sellas Life Sciences Group Inc
1.80 182.59M 0 -37.34M -36.91M -1.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2021-07-21 開始されました Cantor Fitzgerald Overweight
2018-11-01 開始されました Oppenheimer Outperform
2018-04-02 開始されました H.C. Wainwright Buy
2018-03-19 アップグレード Maxim Group Hold → Buy

Sellas Life Sciences Group Inc (SLS) 最新ニュース

pulisher
Jul 25, 2025

What analysts say about SELLAS Life Sciences Group Inc. stockExplosive portfolio gains - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

SELLAS Life Sciences Group Inc. Stock Analysis and ForecastTriple-digit profit margins - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What institutions are buying SELLAS Life Sciences Group Inc. stock nowStrong return on assets - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

What drives SELLAS Life Sciences Group Inc. stock priceFree Stock Market Real-Time Monitoring - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Is SELLAS Life Sciences Group Inc. a good long term investmentTurbocharged investment results - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives USEA stock priceMassive wealth growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 20, 2025

What makes SELLAS Life Sciences Group Inc. stock attractive to long term investorsMomentum Swing Watchlist - beatles.ru

Jul 20, 2025
pulisher
Jul 18, 2025

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Expected to Rise, Maxim Group Analyst Says - Defense World

Jul 18, 2025
pulisher
Jul 16, 2025

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities - Finansavisen

Jul 16, 2025
pulisher
Jul 16, 2025

Sellas Life Sciences shares fall 1.58% premarket after meeting primary endpoints in Phase 2 trial. - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

SELLAS Meets All Primary Endpoints in Phase 2 Trial of - GlobeNewswire

Jul 16, 2025
pulisher
Jul 15, 2025

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success - insights.citeline.com

Jul 15, 2025
pulisher
Jul 15, 2025

What makes SELLAS Life Sciences Group Inc. stock price move sharplyReal Time Breakout Tracking - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How SELLAS Life Sciences Group Inc. stock performs during market volatilityHigh Yield Opportunities - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Sellas Flat on Trial Success - Baystreet.ca

Jul 15, 2025
pulisher
Jul 15, 2025

Sellas Life Sciences Meets Primary Endpoints in Mid-Stage SLS009 Trial - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

SELLAS gains on mid-stage trial win for leukemia drug (SLS) - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

SELLAS' Phase 2 Study Of SLS009 In Acute Myeloid Leukemia Meets All Primary Goals - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

Why SELLAS Life Sciences Group Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

SELLAS Life Sciences Group Reports Positive Phase 2 Trial Results for SLS009 in Relapsed/Refractory Acute Myeloid Leukemia - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study - The Manila Times

Jul 15, 2025
pulisher
Jul 10, 2025

SELLAS Life Sciences Soars 14.21% on Key Appointment - AInvest

Jul 10, 2025
pulisher
Jul 09, 2025

SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Market Movement, Down and Up - investchronicle.com

Jul 09, 2025

Sellas Life Sciences Group Inc (SLS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
大文字化:     |  ボリューム (24 時間):